Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial)

Neublastin (BG00010) is a first-in-class, glial cell–derived neurotrophic factor shown in preclinical studies and an early clinical trial to have potential for the treatment of neuropathic pain. SPRINT was a phase 2, multicenter, double-blinded, placebo-controlled study to evaluate efficacy/safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Backonja, Miroslav, Williams, Leslie, Miao, Xiaopeng, Katz, Nathaniel, Chen, Crystal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761750/
https://www.ncbi.nlm.nih.gov/pubmed/28746076
http://dx.doi.org/10.1097/j.pain.0000000000000983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761750/
https://www.ncbi.nlm.nih.gov/pubmed/28746076
http://dx.doi.org/10.1097/j.pain.0000000000000983

Ejemplares similares